Company intelligence / Profile preview

Wuhan Medicine Valley Technology Development

Ownership: Private
Development stage: Other

Overview

Wuhan Medicine Valley Technology Development Co., Ltd. is a Chinese biotech/pharma company focused on herbal medicines for respiratory and infectious diseases. Its lead asset, Susu Xiaoer Zhike Granules, is in Phase 3 clinical trials for acute onset cough. No detailed clinical results are provided publicly, but the program has reached late-stage development as of early 2025[5].

Therapeutic areas: Pulmonology
Modalities: Herbal medicine
Industry: Biotech

Drug pipeline

2 assets

xiangju rupining

1 more asset in the full pipeline.

Beyond the preview

Go deeper on Wuhan Medicine Valley Technology Development.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Wuhan Medicine Valley Technology Development.